Sarfez Pharmaceuticals


Sarfez Pharmaceuticals is a cardiovascular specialty company dedicated to improving existing drugs through innovative technologies and clinical experiences. They focus on developing safer and better medications for heart failure, kidney diseases, and uncontrolled hypertension, with an emphasis on affordability and price transparency. Their mission involves leveraging advanced drug delivery systems, clinical expertise, and strategic collaborations to enhance patient outcomes and reduce healthcare costs.

Industries

health-care
pharmaceutical

Nr. of Employees

small (1-50)

Sarfez Pharmaceuticals

8000 Towers, Crescent Drive, Suite 1302, Vienna, VA 22182


Patents

Methods of treatment comprising torsemide

US-10596119-B1

View Details

Treatments and formulations comprising Torsemide

US-10463622-B2

View Details

Controlled-release formulations comprising Torsemide

US-10154963-B2

View Details

Products

Torsemide extended-release tablets (loop diuretic)

Oral torsemide tablets formulated as an extended-release loop diuretic for treatment of edema associated with heart failure and renal disease; dosing guidance and safety information provided in prescribing information.


Services

Development and licensing of formulation platforms for extended-release, orally-disintegrating and self-emulsifying oral products to improve pharmacokinetics and bioavailability.

Protocol development, clinical trial design, data interpretation and management of regulatory submissions including interactions with regulatory authorities.

Management of sample requests for licensed practitioners and coordination with mail-order pharmacies to deliver product to patients.

Management of strategic alliances with specialized contract organizations and academic partners to enable a virtual, lower-cost development model.

Expertise Areas

  • Formulation development and drug delivery
  • Clinical trial management and protocol development
  • Cardio-renal therapeutics (heart failure, kidney disease, hypertension)
  • Regulatory compliance and FDA submissions
  • Show More (4)

Key Technologies

  • Matrix-based extended-release (MEXFOR)
  • Orally-disintegrating tablet technology
  • Self-emulsifying drug delivery systems (SEEDS)
  • Oral solid/liquid and injectable dosage form development
  • Show More (3)

News & Updates

A study on bladder dysfunction and overactive bladder symptoms related to loop diuretics.

Research on the short duration of action of loop diuretics and its effect on salt loss and sodium retention.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.